H.R. 7775 — Introduced in House

I 117th CONGRESS 2d Session H. R. 7775 IN THE HOUSE OF REPRESENTATIVES May 13, 2022Mr. Tonko (for himself, Mr. Smith of New Jersey, and Ms. Waters) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To extend the National Alzheimer’s Project. 1. Short title This Act may be cited as the NAPA Reauthorization Act. 2. Extension of project Section 2 of the National Alzheimer's Project Act (42 U.S.C. 11225) is amended— (1) in subsection (c)— (A) in paragraph (2), by striking and coordination of and inserting on, and coordination of,; (B) in paragraph (4)— (i) by redesignating subparagraphs (A) and (B) as subparagraphs (B) and (C), respectively; and (ii) by inserting before subparagraph (B), as so redesignated, the following: (A) promotion of healthy aging and reduction of risk factors for Alzheimer's disease; ; (C) in paragraph (5), by striking ; and and inserting a semicolon; (D) by redesignating paragraph (6) as paragraph (7); and (E) by inserting after paragraph (5) the following: (6) provide information on, and promote the adoption of, healthy behaviors that may reduce the risk of cognitive decline and promote and protect cognitive health; and ; (2) in subsection (d)(2)— (A) by inserting , across public and private sectors, after Nation's progress; and (B) by inserting , including consideration of public-private collaborations, as appropriate before the period; (3) in subsection (e)— (A) in paragraph (2)— (i) in subparagraph (A), by adding at the end the following: (xi) A designee of the Department of Justice. (xii) A designee of the Federal Emergency Management Agency. (xiii) A designee of the Social Security Administration. (xiv) A designee of the Office of Management and Budget. ; and (ii) in subparagraph (B)— (I) in clause (v)— (aa) by striking 2 researchers and inserting 3 researchers; and (bb) by striking ; and and inserting , including at least one researcher with demonstrated experience in recruitment and retention of diverse cohorts of trial participants;; (II) in clause (vi), by striking the period and inserting ; and; and (III) by adding at the end the following: (vii) an individual with a diagnosis of Alzheimer's disease. ; (B) in paragraph (5)— (i) in subparagraph (A)— (I) by striking an initial evaluation and inserting annual evaluations; and (II) by striking research, clinical and inserting research, risk reduction, public health, clinical; (ii) in subparagraph (B), by striking initial; (iii) in subparagraph (C)— (I) in the matter preceding clause (i), by striking initial; and (II) in clause (ii), by inserting and reduce disparities before the semicolon; and (iv) in subparagraph (D), by striking annually thereafter, an evaluation and inserting annual evaluations; and (C) in paragraph (6), by striking 2025 and inserting 2035; (4) in subsection (g)(3)(A)(ii), by inserting and reduce disparities before the semicolon; and (5) in subsection (h), by striking 2025 and inserting 2035.